{"congress":"ASCO2026","meeting_name":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"total_abstracts":7026,"filtered":500,"offset":0,"limit":50,"has_more":true,"abstracts":[{"abstract_id":"2026-9976","abstract_number":"9976","doi":"10.1200/JCO.2026.44.17_suppl.9976","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Education Session","title":"Education Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-05","time_local":"14:15","room":"S100A"},"title":"Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-569 study)","authors":[{"name":"F. Andre","affiliation":"Princess Margaret Cancer Centre","is_presenter":true},{"name":"J. Cortes","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"G. Curigliano","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"M. Reck","affiliation":"Stanford Cancer Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-569","nct_id":"NCT82451698","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":16.4,"unit":"months","hr":0.85,"hr_ci95":[0.75,0.95],"p":"<0.001"},{"name":"PFS","value":9.1,"unit":"months","hr":0.87,"hr_ci95":[0.78,0.99],"p":"<0.001"},{"name":"ORR","value":50.7,"unit":"percent"}],"summary":"Median OS 16.4 months. HR 0.85 (95% CI 0.75–0.95). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-05T14:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9479","abstract_number":"9479","doi":"10.1200/JCO.2026.44.17_suppl.9479","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Small Cell","date":"2026-06-05","time_local":"16:30","room":"Hall B1"},"title":"Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-419 study)","authors":[{"name":"N. Rizvi","affiliation":"Stanford Cancer Institute","is_presenter":true},{"name":"E. Winer","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"S. Antonia","affiliation":"Princess Margaret Cancer Centre","is_presenter":false},{"name":"C. Saura","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-419","nct_id":"NCT88358487","phase":"III"},"indication":"SCLC","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":14.9,"unit":"months","hr":0.83,"hr_ci95":[0.74,0.92],"p":"<0.001"},{"name":"PFS","value":6.1,"unit":"months","hr":0.81,"hr_ci95":[0.76,0.89],"p":"<0.001"},{"name":"ORR","value":63,"unit":"percent"}],"summary":"Median OS 14.9 months. HR 0.83 (95% CI 0.74–0.92). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T16:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-TPS8002","abstract_number":"TPS8002","doi":"10.1200/JCO.2026.44.17_suppl.TPS8002","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Trials in Progress Poster Session","title":"Trials in Progress Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-01","time_local":"20:15","room":"E450"},"title":"Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-16","authors":[{"name":"T. Mok","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":true},{"name":"H. Rugo","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"H. Borghaei","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"G. Curigliano","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-16","nct_id":"NCT45181053","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":19.6,"unit":"months","hr":0.75,"hr_ci95":[0.64,0.86],"p":"0.002"},{"name":"PFS","value":10.1,"unit":"months","hr":0.74,"hr_ci95":[0.64,0.88],"p":"0.002"},{"name":"ORR","value":51.2,"unit":"percent"}],"summary":"Median OS 19.6 months. HR 0.75 (95% CI 0.64–0.86). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-01T20:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1585","abstract_number":"1585","doi":"10.1200/JCO.2026.44.17_suppl.1585","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Breast Cancer—Metastatic","date":"2026-06-02","time_local":"14:45","room":"Hall B1"},"title":"Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-349","authors":[{"name":"N. Rizvi","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":true},{"name":"M.C. Garassino","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"H. Rugo","affiliation":"Massachusetts General Hospital","is_presenter":false}],"sponsor":"Pfizer","trial":{"name":"PALOMA-349","nct_id":"NCT90598054","phase":"II"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"palbociclib","brand":"Ibrance","moa":"CDK4/6 inhibitor"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":37.6,"unit":"months","hr":0.68,"hr_ci95":[0.56,0.8],"p":"<0.001"},{"name":"PFS","value":23.6,"unit":"months","hr":0.67,"hr_ci95":[0.53,0.78],"p":"<0.001"},{"name":"ORR","value":78,"unit":"percent"}],"summary":"Median OS 37.6 months. HR 0.68 (95% CI 0.56–0.8). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T14:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1969","abstract_number":"1969","doi":"10.1200/JCO.2026.44.17_suppl.1969","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"21:00","room":"Arie Crown Theater"},"title":"Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-449","authors":[{"name":"J. Cortes","affiliation":"Cleveland Clinic","is_presenter":true},{"name":"M.C. Garassino","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false},{"name":"P. Schmid","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-449","nct_id":"NCT18767167","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":23.5,"unit":"months","hr":0.86,"hr_ci95":[0.75,0.97],"p":"0.014"},{"name":"PFS","value":9.9,"unit":"months","hr":0.87,"hr_ci95":[0.73,0.98],"p":"0.014"},{"name":"ORR","value":50.8,"unit":"percent"}],"summary":"Median OS 23.5 months. HR 0.86 (95% CI 0.75–0.97). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T21:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1997","abstract_number":"1997","doi":"10.1200/JCO.2026.44.17_suppl.1997","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Breast Cancer—Metastatic","date":"2026-06-04","time_local":"19:15","room":"S100A"},"title":"Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer","authors":[{"name":"G. Curigliano","affiliation":"Chinese University of Hong Kong","is_presenter":true},{"name":"F. Andre","affiliation":"University of Chicago","is_presenter":false},{"name":"L. Paz-Ares","affiliation":"Karolinska Institute","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"OlympiA-594","nct_id":"NCT43314812","phase":"II"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"olaparib","brand":"Lynparza","moa":"PARP inhibitor"},"comparator":"standard of care","endpoints":[{"name":"OS","value":38,"unit":"months","hr":0.62,"hr_ci95":[0.48,0.76],"p":"0.014"},{"name":"PFS","value":23.1,"unit":"months","hr":0.61,"hr_ci95":[0.47,0.76],"p":"0.014"},{"name":"ORR","value":63.1,"unit":"percent"}],"summary":"Median OS 38 months. HR 0.62 (95% CI 0.48–0.76). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T19:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9906","abstract_number":"9906","doi":"10.1200/JCO.2026.44.17_suppl.9906","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Small Cell","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Small Cell","date":"2026-06-01","time_local":"20:45","room":"S406"},"title":"KEYNOTE-849: Keytruda (pembrolizumab) 2L in SCLC","authors":[{"name":"L. Paz-Ares","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"J. Cortes","affiliation":"Royal Marsden Hospital","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-849","nct_id":"NCT63930156","phase":"II"},"indication":"SCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":10.6,"unit":"months","hr":0.89,"hr_ci95":[0.77,0.99],"p":"0.014"},{"name":"PFS","value":4.3,"unit":"months","hr":0.87,"hr_ci95":[0.74,0.99],"p":"0.014"},{"name":"ORR","value":61.3,"unit":"percent"}],"summary":"Median OS 10.6 months. HR 0.89 (95% CI 0.77–0.99). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-01T20:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-4390","abstract_number":"4390","doi":"10.1200/JCO.2026.44.17_suppl.4390","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Gastrointestinal Cancer","session":{"type":"Poster Session","title":"Poster Session: Gastrointestinal Cancer","date":"2026-06-04","time_local":"15:30","room":"E450"},"title":"Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-190","authors":[{"name":"C. Saura","affiliation":"Royal Marsden Hospital","is_presenter":true},{"name":"L. Paz-Ares","affiliation":"Chinese University of Hong Kong","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-190","nct_id":"NCT97449766","phase":"III"},"indication":"biliary tract","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":12.7,"unit":"months","hr":0.83,"hr_ci95":[0.72,0.94],"p":"0.08"},{"name":"PFS","value":7.5,"unit":"months","hr":0.83,"hr_ci95":[0.69,0.97],"p":"0.08"},{"name":"ORR","value":34.7,"unit":"percent"}],"summary":"Median OS 12.7 months. HR 0.83 (95% CI 0.72–0.94). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-04T15:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1347","abstract_number":"1347","doi":"10.1200/JCO.2026.44.17_suppl.1347","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Breast Cancer—Metastatic","date":"2026-06-01","time_local":"21:00","room":"S406"},"title":"Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-560","authors":[{"name":"J. Brahmer","affiliation":"National Cancer Center Japan","is_presenter":true},{"name":"M. Reck","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false},{"name":"H. Rugo","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false},{"name":"G. Curigliano","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false},{"name":"L. Paz-Ares","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-560","nct_id":"NCT60389648","phase":"II"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":18,"unit":"months","hr":0.83,"hr_ci95":[0.71,0.95],"p":"0.03"},{"name":"PFS","value":11,"unit":"months","hr":0.81,"hr_ci95":[0.74,0.94],"p":"0.03"},{"name":"ORR","value":41.2,"unit":"percent"}],"summary":"Median OS 18 months. HR 0.83 (95% CI 0.71–0.95). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-01T21:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-LBA4009","abstract_number":"LBA4009","doi":"10.1200/JCO.2026.44.17_suppl.LBA4009","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Late-Breaking Oral Abstract Session","title":"Late-Breaking Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-03","time_local":"15:45","room":"S100A"},"title":"Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-845","authors":[{"name":"M. Krop","affiliation":"University of Chicago","is_presenter":true},{"name":"E. Winer","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"S. Antonia","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"H. Rugo","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"S. Tolaney","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-845","nct_id":"NCT53991773","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":29.2,"unit":"months","hr":0.58,"hr_ci95":[0.48,0.68],"p":"<0.001"},{"name":"PFS","value":10.6,"unit":"months","hr":0.55,"hr_ci95":[0.44,0.65],"p":"<0.001"},{"name":"ORR","value":47.7,"unit":"percent"}],"summary":"Median OS 29.2 months. HR 0.58 (95% CI 0.48–0.68). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-03T15:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1712","abstract_number":"1712","doi":"10.1200/JCO.2026.44.17_suppl.1712","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Breast Cancer—Metastatic","date":"2026-06-01","time_local":"15:00","room":"Arie Crown Theater"},"title":"Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer","authors":[{"name":"S. Peters","affiliation":"Institut Gustave Roussy","is_presenter":true},{"name":"C. Saura","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false}],"sponsor":"Novartis","trial":{"name":"MONALEESA-38","nct_id":"NCT60056504","phase":"III"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"ribociclib","brand":"Kisqali","moa":"CDK4/6 inhibitor"},"comparator":"standard of care","endpoints":[{"name":"OS","value":33.8,"unit":"months","hr":0.8,"hr_ci95":[0.71,0.89],"p":"<0.001"},{"name":"PFS","value":22.8,"unit":"months","hr":0.77,"hr_ci95":[0.69,0.86],"p":"<0.001"},{"name":"ORR","value":77.9,"unit":"percent"}],"summary":"Median OS 33.8 months. HR 0.8 (95% CI 0.71–0.89). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-01T15:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-4319","abstract_number":"4319","doi":"10.1200/JCO.2026.44.17_suppl.4319","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Session","title":"Poster Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-05","time_local":"18:15","room":"E450"},"title":"Long-term follow-up of Trodelvy 3L+ for urothelial carcinoma: ASCENT-421","authors":[{"name":"R. Herbst","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":true},{"name":"S. Modi","affiliation":"Mayo Clinic","is_presenter":false},{"name":"M. Reck","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"M. Krop","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Gilead","trial":{"name":"ASCENT-421","nct_id":"NCT53826507","phase":"III"},"indication":"urothelial carcinoma","intervention":{"drug_inn":"sacituzumab govitecan","brand":"Trodelvy","moa":"anti-Trop-2 ADC"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":12.5,"unit":"months","hr":0.8,"hr_ci95":[0.72,0.88],"p":"<0.001"},{"name":"PFS","value":8.7,"unit":"months","hr":0.8,"hr_ci95":[0.69,0.84],"p":"<0.001"},{"name":"ORR","value":31.6,"unit":"percent"}],"summary":"Median OS 12.5 months. HR 0.8 (95% CI 0.72–0.88). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-05T18:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-6467","abstract_number":"6467","doi":"10.1200/JCO.2026.44.17_suppl.6467","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-02","time_local":"15:45","room":"S100A"},"title":"Real-world effectiveness of Opdivo vs standard of care in RCC","authors":[{"name":"C. Robert","affiliation":"University of Chicago","is_presenter":true},{"name":"G. Curigliano","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"S. Antonia","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-903","nct_id":"NCT76925924","phase":"III"},"indication":"RCC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":51.4,"unit":"months","hr":0.83,"hr_ci95":[0.74,0.92],"p":"0.03"},{"name":"PFS","value":23.3,"unit":"months","hr":0.83,"hr_ci95":[0.75,0.92],"p":"0.03"},{"name":"ORR","value":55.7,"unit":"percent"}],"summary":"Median OS 51.4 months. HR 0.83 (95% CI 0.74–0.92). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-02T15:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9786","abstract_number":"9786","doi":"10.1200/JCO.2026.44.17_suppl.9786","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Rapid Oral Abstract Session","title":"Rapid Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-02","time_local":"15:00","room":"S100A"},"title":"Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-312 study)","authors":[{"name":"J. Cortes","affiliation":"National Cancer Center Japan","is_presenter":true},{"name":"F. Andre","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"C. Saura","affiliation":"University of Chicago","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-312","nct_id":"NCT74476517","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":28.5,"unit":"months","hr":0.68,"hr_ci95":[0.55,0.81],"p":"<0.001"},{"name":"PFS","value":8.8,"unit":"months","hr":0.69,"hr_ci95":[0.54,0.82],"p":"<0.001"},{"name":"ORR","value":44.2,"unit":"percent"}],"summary":"Median OS 28.5 months. HR 0.68 (95% CI 0.55–0.81). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T15:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9760","abstract_number":"9760","doi":"10.1200/JCO.2026.44.17_suppl.9760","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-03","time_local":"14:30","room":"Arie Crown Theater"},"title":"FLAURA-898: Tagrisso (osimertinib) 2L in NSCLC","authors":[{"name":"G. Curigliano","affiliation":"Institut Gustave Roussy","is_presenter":true},{"name":"F. Andre","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"M.C. Garassino","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"S. Peters","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"P. Schmid","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-898","nct_id":"NCT65454622","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":22.5,"unit":"months","hr":0.76,"hr_ci95":[0.66,0.86],"p":"0.08"},{"name":"PFS","value":10.5,"unit":"months","hr":0.76,"hr_ci95":[0.68,0.84],"p":"0.08"},{"name":"ORR","value":59.6,"unit":"percent"}],"summary":"Median OS 22.5 months. HR 0.76 (95% CI 0.66–0.86). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-03T14:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1438","abstract_number":"1438","doi":"10.1200/JCO.2026.44.17_suppl.1438","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Rapid Oral Abstract Session","title":"Rapid Oral Abstract Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"20:30","room":"S100A"},"title":"MONARCH-789: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer","authors":[{"name":"A. Spira","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"M.C. Garassino","affiliation":"Stanford Cancer Institute","is_presenter":false}],"sponsor":"Eli Lilly","trial":{"name":"MONARCH-789","nct_id":"NCT81284428","phase":"II"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"abemaciclib","brand":"Verzenio","moa":"CDK4/6 inhibitor"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":37.2,"unit":"months","hr":0.87,"hr_ci95":[0.75,0.99],"p":"0.002"},{"name":"PFS","value":24.7,"unit":"months","hr":0.85,"hr_ci95":[0.74,0.99],"p":"0.002"},{"name":"ORR","value":58.8,"unit":"percent"}],"summary":"Median OS 37.2 months. HR 0.87 (95% CI 0.75–0.99). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T20:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1284","abstract_number":"1284","doi":"10.1200/JCO.2026.44.17_suppl.1284","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"16:00","room":"Hall B1"},"title":"Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer","authors":[{"name":"M. Krop","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":true},{"name":"M.C. Garassino","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"S. Modi","affiliation":"Mayo Clinic","is_presenter":false},{"name":"C. Saura","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false}],"sponsor":"Eli Lilly","trial":{"name":"MONARCH-149","nct_id":"NCT32526973","phase":"III"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"abemaciclib","brand":"Verzenio","moa":"CDK4/6 inhibitor"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":38.9,"unit":"months","hr":0.58,"hr_ci95":[0.47,0.69],"p":"0.002"},{"name":"PFS","value":19.4,"unit":"months","hr":0.6,"hr_ci95":[0.48,0.7],"p":"0.002"},{"name":"ORR","value":74.7,"unit":"percent"}],"summary":"Median OS 38.9 months. HR 0.58 (95% CI 0.47–0.69). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T16:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9578","abstract_number":"9578","doi":"10.1200/JCO.2026.44.17_suppl.9578","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-04","time_local":"16:00","room":"S100A"},"title":"Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-645","authors":[{"name":"C. Robert","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":true},{"name":"S. Peters","affiliation":"Stanford Cancer Institute","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-645","nct_id":"NCT22264892","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":22.4,"unit":"months","hr":0.6,"hr_ci95":[0.5,0.7],"p":"0.002"},{"name":"PFS","value":7.7,"unit":"months","hr":0.64,"hr_ci95":[0.49,0.67],"p":"0.002"},{"name":"ORR","value":45.7,"unit":"percent"}],"summary":"Median OS 22.4 months. HR 0.6 (95% CI 0.5–0.7). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-04T16:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9592","abstract_number":"9592","doi":"10.1200/JCO.2026.44.17_suppl.9592","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-04","time_local":"18:45","room":"Hall B1"},"title":"Quality of life outcomes with Keytruda in patients with NSCLC","authors":[{"name":"M. Krop","affiliation":"National Cancer Center Japan","is_presenter":true},{"name":"M. Reck","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"S. Peters","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"N. Rizvi","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-433","nct_id":"NCT65945184","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":25.6,"unit":"months","hr":0.79,"hr_ci95":[0.7,0.88],"p":"0.014"},{"name":"PFS","value":11.7,"unit":"months","hr":0.77,"hr_ci95":[0.66,0.89],"p":"0.014"},{"name":"ORR","value":61.9,"unit":"percent"}],"summary":"Median OS 25.6 months. HR 0.79 (95% CI 0.7–0.88). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-04T18:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9730","abstract_number":"9730","doi":"10.1200/JCO.2026.44.17_suppl.9730","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-01","time_local":"15:15","room":"E450"},"title":"Real-world effectiveness of Enhertu vs standard of care in NSCLC","authors":[{"name":"F. Andre","affiliation":"Princess Margaret Cancer Centre","is_presenter":true},{"name":"E. Winer","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false}],"sponsor":"Daiichi Sankyo","trial":{"name":"DESTINY-Breast-376","nct_id":"NCT30918589","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"trastuzumab deruxtecan","brand":"Enhertu","moa":"anti-HER2 ADC"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":29.4,"unit":"months","hr":0.85,"hr_ci95":[0.76,0.94],"p":"0.014"},{"name":"PFS","value":7.2,"unit":"months","hr":0.89,"hr_ci95":[0.8,0.91],"p":"0.014"},{"name":"ORR","value":50.6,"unit":"percent"}],"summary":"Median OS 29.4 months. HR 0.85 (95% CI 0.76–0.94). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-01T15:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9693","abstract_number":"9693","doi":"10.1200/JCO.2026.44.17_suppl.9693","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-04","time_local":"13:00","room":"S406"},"title":"Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-881","authors":[{"name":"T. Mok","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":true},{"name":"C. Robert","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"F. Andre","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-881","nct_id":"NCT08001951","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":29.3,"unit":"months","hr":0.6,"hr_ci95":[0.51,0.69],"p":"0.014"},{"name":"PFS","value":7.4,"unit":"months","hr":0.61,"hr_ci95":[0.51,0.72],"p":"0.014"},{"name":"ORR","value":60,"unit":"percent"}],"summary":"Median OS 29.3 months. HR 0.6 (95% CI 0.51–0.69). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-04T13:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-5235","abstract_number":"5235","doi":"10.1200/JCO.2026.44.17_suppl.5235","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Prostate","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Genitourinary Cancer—Prostate","date":"2026-06-04","time_local":"16:45","room":"Arie Crown Theater"},"title":"Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-650","authors":[{"name":"T. Mok","affiliation":"Dana-Farber Cancer Institute","is_presenter":true},{"name":"R. Herbst","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"M. Reck","affiliation":"Massachusetts General Hospital","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"OlympiA-650","nct_id":"NCT23801137","phase":"II"},"indication":"prostate","intervention":{"drug_inn":"olaparib","brand":"Lynparza","moa":"PARP inhibitor"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":37.5,"unit":"months","hr":0.87,"hr_ci95":[0.76,0.98],"p":"0.08"},{"name":"PFS","value":20.3,"unit":"months","hr":0.89,"hr_ci95":[0.75,0.99],"p":"0.08"},{"name":"ORR","value":46.8,"unit":"percent"}],"summary":"Median OS 37.5 months. HR 0.87 (95% CI 0.76–0.98). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-04T16:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1891","abstract_number":"1891","doi":"10.1200/JCO.2026.44.17_suppl.1891","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-02","time_local":"20:30","room":"E450"},"title":"Real-world effectiveness of Keytruda vs standard of care in TNBC","authors":[{"name":"H. Borghaei","affiliation":"Mayo Clinic","is_presenter":true},{"name":"S. Modi","affiliation":"National Cancer Center Japan","is_presenter":false},{"name":"H. Rugo","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"R. Herbst","affiliation":"Princess Margaret Cancer Centre","is_presenter":false}],"sponsor":"Merck","trial":{"name":"KEYNOTE-968","nct_id":"NCT24586311","phase":"II"},"indication":"TNBC","intervention":{"drug_inn":"pembrolizumab","brand":"Keytruda","moa":"anti-PD-1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":24,"unit":"months","hr":0.81,"hr_ci95":[0.69,0.93],"p":"0.014"},{"name":"PFS","value":7.2,"unit":"months","hr":0.79,"hr_ci95":[0.7,0.97],"p":"0.014"},{"name":"ORR","value":40.4,"unit":"percent"}],"summary":"Median OS 24 months. HR 0.81 (95% CI 0.69–0.93). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-02T20:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-4854","abstract_number":"4854","doi":"10.1200/JCO.2026.44.17_suppl.4854","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Gastrointestinal Cancer","session":{"type":"Education Session","title":"Education Session: Gastrointestinal Cancer","date":"2026-06-02","time_local":"14:30","room":"S100A"},"title":"CheckMate-957: Opdivo (nivolumab) neoadjuvant in HCC","authors":[{"name":"M.C. Garassino","affiliation":"Stanford Cancer Institute","is_presenter":true},{"name":"C. Saura","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"S. Antonia","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-957","nct_id":"NCT64844073","phase":"II"},"indication":"HCC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":19.2,"unit":"months","hr":0.62,"hr_ci95":[0.51,0.73],"p":"0.08"},{"name":"PFS","value":8.6,"unit":"months","hr":0.64,"hr_ci95":[0.54,0.74],"p":"0.08"},{"name":"ORR","value":32.5,"unit":"percent"}],"summary":"Median OS 19.2 months. HR 0.62 (95% CI 0.51–0.73). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-02T14:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1684","abstract_number":"1684","doi":"10.1200/JCO.2026.44.17_suppl.1684","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-02","time_local":"19:30","room":"E450"},"title":"Quality of life outcomes with Kisqali in patients with HR+ breast cancer","authors":[{"name":"F. Andre","affiliation":"University of Chicago","is_presenter":true},{"name":"J. Brahmer","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false}],"sponsor":"Novartis","trial":{"name":"MONALEESA-190","nct_id":"NCT77693036","phase":"III"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"ribociclib","brand":"Kisqali","moa":"CDK4/6 inhibitor"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":35.6,"unit":"months","hr":0.7,"hr_ci95":[0.62,0.78],"p":"0.08"},{"name":"PFS","value":20.5,"unit":"months","hr":0.74,"hr_ci95":[0.66,0.81],"p":"0.08"},{"name":"ORR","value":55.5,"unit":"percent"}],"summary":"Median OS 35.6 months. HR 0.7 (95% CI 0.62–0.78). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T19:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1629","abstract_number":"1629","doi":"10.1200/JCO.2026.44.17_suppl.1629","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"13:15","room":"S100A"},"title":"Quality of life outcomes with Ibrance in patients with HR+ breast cancer","authors":[{"name":"T. Mok","affiliation":"Mayo Clinic","is_presenter":true},{"name":"E. Winer","affiliation":"Dana-Farber Cancer Institute","is_presenter":false}],"sponsor":"Pfizer","trial":{"name":"PALOMA-223","nct_id":"NCT98838794","phase":"II"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"palbociclib","brand":"Ibrance","moa":"CDK4/6 inhibitor"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":38.2,"unit":"months","hr":0.9,"hr_ci95":[0.8,0.99],"p":"<0.001"},{"name":"PFS","value":27.1,"unit":"months","hr":0.86,"hr_ci95":[0.8,0.95],"p":"<0.001"},{"name":"ORR","value":57.2,"unit":"percent"}],"summary":"Median OS 38.2 months. HR 0.9 (95% CI 0.8–0.99). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T13:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1930","abstract_number":"1930","doi":"10.1200/JCO.2026.44.17_suppl.1930","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Breast Cancer—Metastatic","date":"2026-06-03","time_local":"14:45","room":"Hall B1"},"title":"Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-410 study)","authors":[{"name":"S. Modi","affiliation":"Massachusetts General Hospital","is_presenter":true},{"name":"T. Mok","affiliation":"Massachusetts General Hospital","is_presenter":false},{"name":"H. Rugo","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"M. Reck","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"P. Schmid","affiliation":"Massachusetts General Hospital","is_presenter":false}],"sponsor":"Eli Lilly","trial":{"name":"MONARCH-410","nct_id":"NCT12503018","phase":"III"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"abemaciclib","brand":"Verzenio","moa":"CDK4/6 inhibitor"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":36.7,"unit":"months","hr":0.9,"hr_ci95":[0.77,0.99],"p":"0.014"},{"name":"PFS","value":22.3,"unit":"months","hr":0.93,"hr_ci95":[0.8,0.99],"p":"0.014"},{"name":"ORR","value":58.8,"unit":"percent"}],"summary":"Median OS 36.7 months. HR 0.9 (95% CI 0.77–0.99). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-03T14:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1577","abstract_number":"1577","doi":"10.1200/JCO.2026.44.17_suppl.1577","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-04","time_local":"20:30","room":"E450"},"title":"Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-252","authors":[{"name":"A. Spira","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"L. Paz-Ares","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false}],"sponsor":"Eli Lilly","trial":{"name":"MONARCH-252","nct_id":"NCT49268597","phase":"III"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"abemaciclib","brand":"Verzenio","moa":"CDK4/6 inhibitor"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":33.1,"unit":"months","hr":0.68,"hr_ci95":[0.6,0.76],"p":"<0.001"},{"name":"PFS","value":21.5,"unit":"months","hr":0.65,"hr_ci95":[0.6,0.78],"p":"<0.001"},{"name":"ORR","value":74.8,"unit":"percent"}],"summary":"Median OS 33.1 months. HR 0.68 (95% CI 0.6–0.76). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T20:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-e12028","abstract_number":"e12028","doi":"10.1200/JCO.2026.44.17_suppl.e12028","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Gastrointestinal Cancer","session":{"type":"Publication Only","title":"Publication Only: Gastrointestinal Cancer","date":"2026-06-03","time_local":"14:00","room":"S406"},"title":"DESTINY-Breast-179: Enhertu (trastuzumab deruxtecan) adjuvant in gastric","authors":[{"name":"S. Antonia","affiliation":"MD Anderson Cancer Center","is_presenter":true},{"name":"E. Winer","affiliation":"University of Chicago","is_presenter":false},{"name":"M. Krop","affiliation":"Royal Marsden Hospital","is_presenter":false},{"name":"H. Borghaei","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false},{"name":"L. Paz-Ares","affiliation":"Institut Gustave Roussy","is_presenter":false}],"sponsor":"Daiichi Sankyo","trial":{"name":"DESTINY-Breast-179","nct_id":"NCT43607208","phase":"III"},"indication":"gastric","intervention":{"drug_inn":"trastuzumab deruxtecan","brand":"Enhertu","moa":"anti-HER2 ADC"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":18.8,"unit":"months","hr":0.88,"hr_ci95":[0.74,0.99],"p":"<0.001"},{"name":"PFS","value":7.9,"unit":"months","hr":0.89,"hr_ci95":[0.72,0.97],"p":"<0.001"},{"name":"ORR","value":49.7,"unit":"percent"}],"summary":"Median OS 18.8 months. HR 0.88 (95% CI 0.74–0.99). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-03T14:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9939","abstract_number":"9939","doi":"10.1200/JCO.2026.44.17_suppl.9939","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Education Session","title":"Education Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-04","time_local":"20:00","room":"E450"},"title":"Long-term follow-up of Tecentriq 3L+ for NSCLC: IMpower-860","authors":[{"name":"P. Schmid","affiliation":"Cleveland Clinic","is_presenter":true},{"name":"H. Rugo","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"S. Tolaney","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-860","nct_id":"NCT14419528","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"standard of care","endpoints":[{"name":"OS","value":20.7,"unit":"months","hr":0.88,"hr_ci95":[0.76,0.99],"p":"0.014"},{"name":"PFS","value":11.4,"unit":"months","hr":0.85,"hr_ci95":[0.76,0.96],"p":"0.014"},{"name":"ORR","value":40.1,"unit":"percent"}],"summary":"Median OS 20.7 months. HR 0.88 (95% CI 0.76–0.99). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T20:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9268","abstract_number":"9268","doi":"10.1200/JCO.2026.44.17_suppl.9268","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Rapid Oral Abstract Session","title":"Rapid Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-02","time_local":"20:30","room":"E450"},"title":"Long-term follow-up of Tecentriq 2L for NSCLC: IMpower-605","authors":[{"name":"N. Rizvi","affiliation":"Peter MacCallum Cancer Centre","is_presenter":true},{"name":"S. Peters","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"S. Antonia","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false}],"sponsor":"Roche","trial":{"name":"IMpower-605","nct_id":"NCT61433413","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"atezolizumab","brand":"Tecentriq","moa":"anti-PD-L1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":23.7,"unit":"months","hr":0.73,"hr_ci95":[0.62,0.84],"p":"0.002"},{"name":"PFS","value":11.3,"unit":"months","hr":0.68,"hr_ci95":[0.61,0.81],"p":"0.002"},{"name":"ORR","value":53.8,"unit":"percent"}],"summary":"Median OS 23.7 months. HR 0.73 (95% CI 0.62–0.84). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T20:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-6860","abstract_number":"6860","doi":"10.1200/JCO.2026.44.17_suppl.6860","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Session","title":"Poster Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-05","time_local":"15:45","room":"Arie Crown Theater"},"title":"CheckMate-13: Opdivo (nivolumab) 2L in RCC","authors":[{"name":"A. Spira","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":true},{"name":"G. Curigliano","affiliation":"University of Chicago","is_presenter":false},{"name":"F. Andre","affiliation":"University of Chicago","is_presenter":false},{"name":"N. Rizvi","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false},{"name":"H. Rugo","affiliation":"University of Chicago","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-13","nct_id":"NCT78442350","phase":"II"},"indication":"RCC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":52.8,"unit":"months","hr":0.66,"hr_ci95":[0.54,0.78],"p":"0.002"},{"name":"PFS","value":21.6,"unit":"months","hr":0.69,"hr_ci95":[0.56,0.82],"p":"0.002"},{"name":"ORR","value":63,"unit":"percent"}],"summary":"Median OS 52.8 months. HR 0.66 (95% CI 0.54–0.78). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T15:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-LBA4032","abstract_number":"LBA4032","doi":"10.1200/JCO.2026.44.17_suppl.LBA4032","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Prostate","session":{"type":"Late-Breaking Oral Abstract Session","title":"Late-Breaking Oral Abstract Session: Genitourinary Cancer—Prostate","date":"2026-06-02","time_local":"20:30","room":"Arie Crown Theater"},"title":"Lynparza plus chemotherapy in previously untreated prostate: updated analysis from OlympiA-64","authors":[{"name":"M.C. Garassino","affiliation":"Dana-Farber Cancer Institute","is_presenter":true},{"name":"S. Tolaney","affiliation":"Mayo Clinic","is_presenter":false},{"name":"E. Winer","affiliation":"Royal Marsden Hospital","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"OlympiA-64","nct_id":"NCT11008576","phase":"III"},"indication":"prostate","intervention":{"drug_inn":"olaparib","brand":"Lynparza","moa":"PARP inhibitor"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":36.8,"unit":"months","hr":0.75,"hr_ci95":[0.62,0.88],"p":"0.03"},{"name":"PFS","value":14,"unit":"months","hr":0.71,"hr_ci95":[0.63,0.89],"p":"0.03"},{"name":"ORR","value":36.5,"unit":"percent"}],"summary":"Median OS 36.8 months. HR 0.75 (95% CI 0.62–0.88). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-02T20:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1710","abstract_number":"1710","doi":"10.1200/JCO.2026.44.17_suppl.1710","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"14:00","room":"Hall B1"},"title":"Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-601","authors":[{"name":"R. Herbst","affiliation":"Mayo Clinic","is_presenter":true},{"name":"M.C. Garassino","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false},{"name":"S. Modi","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false}],"sponsor":"Novartis","trial":{"name":"MONALEESA-601","nct_id":"NCT89816647","phase":"III"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"ribociclib","brand":"Kisqali","moa":"CDK4/6 inhibitor"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":32.4,"unit":"months","hr":0.81,"hr_ci95":[0.69,0.93],"p":"0.002"},{"name":"PFS","value":26.1,"unit":"months","hr":0.82,"hr_ci95":[0.69,0.89],"p":"0.002"},{"name":"ORR","value":58.3,"unit":"percent"}],"summary":"Median OS 32.4 months. HR 0.81 (95% CI 0.69–0.93). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T14:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9631","abstract_number":"9631","doi":"10.1200/JCO.2026.44.17_suppl.9631","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-04","time_local":"14:15","room":"S100A"},"title":"Long-term follow-up of Imfinzi 1L for NSCLC: PACIFIC-330","authors":[{"name":"P. Schmid","affiliation":"Massachusetts General Hospital","is_presenter":true},{"name":"A. Spira","affiliation":"Institut Gustave Roussy","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-330","nct_id":"NCT09565501","phase":"II"},"indication":"NSCLC","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":25.2,"unit":"months","hr":0.8,"hr_ci95":[0.69,0.91],"p":"0.03"},{"name":"PFS","value":10.9,"unit":"months","hr":0.83,"hr_ci95":[0.71,0.88],"p":"0.03"},{"name":"ORR","value":43.4,"unit":"percent"}],"summary":"Median OS 25.2 months. HR 0.8 (95% CI 0.69–0.91). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T14:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-4842","abstract_number":"4842","doi":"10.1200/JCO.2026.44.17_suppl.4842","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-04","time_local":"18:30","room":"Arie Crown Theater"},"title":"EV-446: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma","authors":[{"name":"J. Cortes","affiliation":"Mayo Clinic","is_presenter":true},{"name":"J. Brahmer","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false}],"sponsor":"Astellas","trial":{"name":"EV-446","nct_id":"NCT96926655","phase":"III"},"indication":"urothelial carcinoma","intervention":{"drug_inn":"enfortumab vedotin","brand":"Padcev","moa":"anti-Nectin-4 ADC"},"comparator":"placebo + chemotherapy","endpoints":[{"name":"OS","value":16.6,"unit":"months","hr":0.55,"hr_ci95":[0.45,0.65],"p":"0.002"},{"name":"PFS","value":7.2,"unit":"months","hr":0.58,"hr_ci95":[0.44,0.65],"p":"0.002"},{"name":"ORR","value":42,"unit":"percent"}],"summary":"Median OS 16.6 months. HR 0.55 (95% CI 0.45–0.65). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-04T18:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-4321","abstract_number":"4321","doi":"10.1200/JCO.2026.44.17_suppl.4321","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Gastrointestinal Cancer","session":{"type":"Poster Session","title":"Poster Session: Gastrointestinal Cancer","date":"2026-06-01","time_local":"13:30","room":"Arie Crown Theater"},"title":"Real-world effectiveness of Imfinzi vs standard of care in biliary tract","authors":[{"name":"A. Spira","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":true},{"name":"J. Brahmer","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-773","nct_id":"NCT62826043","phase":"II"},"indication":"biliary tract","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":11.6,"unit":"months","hr":0.58,"hr_ci95":[0.48,0.68],"p":"<0.001"},{"name":"PFS","value":7.9,"unit":"months","hr":0.57,"hr_ci95":[0.49,0.64],"p":"<0.001"},{"name":"ORR","value":23.4,"unit":"percent"}],"summary":"Median OS 11.6 months. HR 0.58 (95% CI 0.48–0.68). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-01T13:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-4406","abstract_number":"4406","doi":"10.1200/JCO.2026.44.17_suppl.4406","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Gastrointestinal Cancer","session":{"type":"Poster Session","title":"Poster Session: Gastrointestinal Cancer","date":"2026-06-05","time_local":"18:00","room":"E450"},"title":"Long-term follow-up of Opdivo 3L+ for HCC: CheckMate-238","authors":[{"name":"P. Schmid","affiliation":"Stanford Cancer Institute","is_presenter":true},{"name":"N. Rizvi","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"H. Borghaei","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"Bristol-Myers Squibb","trial":{"name":"CheckMate-238","nct_id":"NCT16067356","phase":"II"},"indication":"HCC","intervention":{"drug_inn":"nivolumab","brand":"Opdivo","moa":"anti-PD-1 mAb"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":13.1,"unit":"months","hr":0.63,"hr_ci95":[0.55,0.71],"p":"<0.001"},{"name":"PFS","value":6.8,"unit":"months","hr":0.58,"hr_ci95":[0.59,0.67],"p":"<0.001"},{"name":"ORR","value":32.6,"unit":"percent"}],"summary":"Median OS 13.1 months. HR 0.63 (95% CI 0.55–0.71). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-05T18:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-5373","abstract_number":"5373","doi":"10.1200/JCO.2026.44.17_suppl.5373","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Prostate","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Genitourinary Cancer—Prostate","date":"2026-06-02","time_local":"15:00","room":"S406"},"title":"Quality of life outcomes with Lynparza in patients with prostate","authors":[{"name":"G. Curigliano","affiliation":"Massachusetts General Hospital","is_presenter":true},{"name":"M. Krop","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"M.C. Garassino","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"C. Saura","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"C. Robert","affiliation":"MD Anderson Cancer Center","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"OlympiA-395","nct_id":"NCT32025393","phase":"III"},"indication":"prostate","intervention":{"drug_inn":"olaparib","brand":"Lynparza","moa":"PARP inhibitor"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":29.3,"unit":"months","hr":0.67,"hr_ci95":[0.56,0.78],"p":"0.08"},{"name":"PFS","value":16.5,"unit":"months","hr":0.67,"hr_ci95":[0.55,0.77],"p":"0.08"},{"name":"ORR","value":39.9,"unit":"percent"}],"summary":"Median OS 29.3 months. HR 0.67 (95% CI 0.56–0.78). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-02T15:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1438","abstract_number":"1438","doi":"10.1200/JCO.2026.44.17_suppl.1438","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Oral Abstract Session","title":"Oral Abstract Session: Breast Cancer—Metastatic","date":"2026-06-02","time_local":"13:45","room":"Arie Crown Theater"},"title":"PALOMA-382: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer","authors":[{"name":"P. Schmid","affiliation":"Royal Marsden Hospital","is_presenter":true},{"name":"M. Reck","affiliation":"Princess Margaret Cancer Centre","is_presenter":false}],"sponsor":"Pfizer","trial":{"name":"PALOMA-382","nct_id":"NCT17117486","phase":"II"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"palbociclib","brand":"Ibrance","moa":"CDK4/6 inhibitor"},"comparator":"standard of care","endpoints":[{"name":"OS","value":36.2,"unit":"months","hr":0.86,"hr_ci95":[0.74,0.98],"p":"0.08"},{"name":"PFS","value":18.6,"unit":"months","hr":0.83,"hr_ci95":[0.74,0.95],"p":"0.08"},{"name":"ORR","value":75.1,"unit":"percent"}],"summary":"Median OS 36.2 months. HR 0.86 (95% CI 0.74–0.98). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-02T13:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9343","abstract_number":"9343","doi":"10.1200/JCO.2026.44.17_suppl.9343","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Session","title":"Poster Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-02","time_local":"20:15","room":"Hall B1"},"title":"Quality of life outcomes with Imfinzi in patients with NSCLC","authors":[{"name":"S. Tolaney","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":true},{"name":"A. Spira","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false},{"name":"C. Robert","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false},{"name":"N. Rizvi","affiliation":"Dana-Farber Cancer Institute","is_presenter":false},{"name":"G. Curigliano","affiliation":"Massachusetts General Hospital","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"PACIFIC-804","nct_id":"NCT81564168","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"durvalumab","brand":"Imfinzi","moa":"anti-PD-L1 mAb"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":21.3,"unit":"months","hr":0.8,"hr_ci95":[0.66,0.94],"p":"0.03"},{"name":"PFS","value":8.6,"unit":"months","hr":0.84,"hr_ci95":[0.64,0.91],"p":"0.03"},{"name":"ORR","value":60.9,"unit":"percent"}],"summary":"Median OS 21.3 months. HR 0.8 (95% CI 0.66–0.94). No new safety signals identified.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-02T20:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1547","abstract_number":"1547","doi":"10.1200/JCO.2026.44.17_suppl.1547","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"21:00","room":"Arie Crown Theater"},"title":"OlympiA-637: Lynparza (olaparib) neoadjuvant in HR+ breast cancer","authors":[{"name":"T. Mok","affiliation":"Peter MacCallum Cancer Centre","is_presenter":true},{"name":"S. Tolaney","affiliation":"Karolinska Institute","is_presenter":false},{"name":"A. Spira","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"OlympiA-637","nct_id":"NCT66724107","phase":"III"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"olaparib","brand":"Lynparza","moa":"PARP inhibitor"},"comparator":"investigator's choice chemotherapy","endpoints":[{"name":"OS","value":29.7,"unit":"months","hr":0.77,"hr_ci95":[0.65,0.89],"p":"0.002"},{"name":"PFS","value":26.6,"unit":"months","hr":0.8,"hr_ci95":[0.64,0.86],"p":"0.002"},{"name":"ORR","value":71.5,"unit":"percent"}],"summary":"Median OS 29.7 months. HR 0.77 (95% CI 0.65–0.89). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T21:00:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1751","abstract_number":"1751","doi":"10.1200/JCO.2026.44.17_suppl.1751","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Clinical Science Symposium","title":"Clinical Science Symposium: Breast Cancer—Metastatic","date":"2026-06-03","time_local":"20:45","room":"S406"},"title":"Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-187","authors":[{"name":"S. Antonia","affiliation":"National Cancer Center Japan","is_presenter":true},{"name":"M. Reck","affiliation":"Cleveland Clinic","is_presenter":false}],"sponsor":"Pfizer","trial":{"name":"PALOMA-187","nct_id":"NCT10869646","phase":"III"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"palbociclib","brand":"Ibrance","moa":"CDK4/6 inhibitor"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":39.7,"unit":"months","hr":0.56,"hr_ci95":[0.44,0.68],"p":"0.08"},{"name":"PFS","value":22.2,"unit":"months","hr":0.54,"hr_ci95":[0.42,0.71],"p":"0.08"},{"name":"ORR","value":55,"unit":"percent"}],"summary":"Median OS 39.7 months. HR 0.56 (95% CI 0.44–0.68). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-03T20:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-4355","abstract_number":"4355","doi":"10.1200/JCO.2026.44.17_suppl.4355","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Session","title":"Poster Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-04","time_local":"14:45","room":"Arie Crown Theater"},"title":"Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma","authors":[{"name":"C. Saura","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":true},{"name":"J. Cortes","affiliation":"Cleveland Clinic","is_presenter":false},{"name":"M. Krop","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"R. Herbst","affiliation":"MD Anderson Cancer Center","is_presenter":false},{"name":"P. Schmid","affiliation":"Karolinska Institute","is_presenter":false}],"sponsor":"Gilead","trial":{"name":"ASCENT-95","nct_id":"NCT67775018","phase":"III"},"indication":"urothelial carcinoma","intervention":{"drug_inn":"sacituzumab govitecan","brand":"Trodelvy","moa":"anti-Trop-2 ADC"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":14.2,"unit":"months","hr":0.78,"hr_ci95":[0.68,0.88],"p":"0.014"},{"name":"PFS","value":8.9,"unit":"months","hr":0.78,"hr_ci95":[0.69,0.9],"p":"0.014"},{"name":"ORR","value":39.8,"unit":"percent"}],"summary":"Median OS 14.2 months. HR 0.78 (95% CI 0.68–0.88). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"medium","embargo":{"lifted_at":"2026-06-04T14:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-9108","abstract_number":"9108","doi":"10.1200/JCO.2026.44.17_suppl.9108","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Lung Cancer—Non-Small Cell Metastatic","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Lung Cancer—Non-Small Cell Metastatic","date":"2026-06-02","time_local":"15:15","room":"S406"},"title":"Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-87","authors":[{"name":"S. Modi","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":true},{"name":"M.C. Garassino","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"A. Spira","affiliation":"Chinese University of Hong Kong","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"FLAURA-87","nct_id":"NCT36311446","phase":"III"},"indication":"NSCLC","intervention":{"drug_inn":"osimertinib","brand":"Tagrisso","moa":"EGFR TKI"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":28.9,"unit":"months","hr":0.69,"hr_ci95":[0.56,0.82],"p":"0.002"},{"name":"PFS","value":7.2,"unit":"months","hr":0.67,"hr_ci95":[0.57,0.83],"p":"0.002"},{"name":"ORR","value":45.2,"unit":"percent"}],"summary":"Median OS 28.9 months. HR 0.69 (95% CI 0.56–0.82). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-02T15:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-5638","abstract_number":"5638","doi":"10.1200/JCO.2026.44.17_suppl.5638","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Prostate","session":{"type":"Rapid Oral Abstract Session","title":"Rapid Oral Abstract Session: Genitourinary Cancer—Prostate","date":"2026-06-03","time_local":"15:45","room":"E450"},"title":"OlympiA-503: Lynparza (olaparib) 1L in prostate","authors":[{"name":"P. Schmid","affiliation":"Peter MacCallum Cancer Centre","is_presenter":true},{"name":"C. Robert","affiliation":"Institut Gustave Roussy","is_presenter":false},{"name":"L. Paz-Ares","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"H. Rugo","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"M.C. Garassino","affiliation":"Memorial Sloan Kettering Cancer Center","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"OlympiA-503","nct_id":"NCT25375054","phase":"II"},"indication":"prostate","intervention":{"drug_inn":"olaparib","brand":"Lynparza","moa":"PARP inhibitor"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":31.5,"unit":"months","hr":0.59,"hr_ci95":[0.51,0.67],"p":"0.002"},{"name":"PFS","value":19.3,"unit":"months","hr":0.59,"hr_ci95":[0.55,0.64],"p":"0.002"},{"name":"ORR","value":48.9,"unit":"percent"}],"summary":"Median OS 31.5 months. HR 0.59 (95% CI 0.51–0.67). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-03T15:45:00-05:00","status":"embargoed"}},{"abstract_id":"2026-4935","abstract_number":"4935","doi":"10.1200/JCO.2026.44.17_suppl.4935","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Genitourinary Cancer—Kidney/Bladder","session":{"type":"Poster Discussion Session","title":"Poster Discussion Session: Genitourinary Cancer—Kidney/Bladder","date":"2026-06-04","time_local":"15:30","room":"S406"},"title":"Long-term follow-up of Padcev 3L+ for urothelial carcinoma: EV-254","authors":[{"name":"J. Brahmer","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":true},{"name":"E. Winer","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"G. Curigliano","affiliation":"Chinese University of Hong Kong","is_presenter":false},{"name":"S. Tolaney","affiliation":"Massachusetts General Hospital","is_presenter":false},{"name":"R. Herbst","affiliation":"University of Chicago","is_presenter":false}],"sponsor":"Astellas","trial":{"name":"EV-254","nct_id":"NCT12288131","phase":"III"},"indication":"urothelial carcinoma","intervention":{"drug_inn":"enfortumab vedotin","brand":"Padcev","moa":"anti-Nectin-4 ADC"},"comparator":"trastuzumab + chemotherapy","endpoints":[{"name":"OS","value":14.7,"unit":"months","hr":0.9,"hr_ci95":[0.79,0.99],"p":"<0.001"},{"name":"PFS","value":6,"unit":"months","hr":0.9,"hr_ci95":[0.77,0.99],"p":"<0.001"},{"name":"ORR","value":44.4,"unit":"percent"}],"summary":"Median OS 14.7 months. HR 0.9 (95% CI 0.79–0.99). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-04T15:30:00-05:00","status":"embargoed"}},{"abstract_id":"2026-TPS8047","abstract_number":"TPS8047","doi":"10.1200/JCO.2026.44.17_suppl.TPS8047","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Trials in Progress Poster Session","title":"Trials in Progress Poster Session: Breast Cancer—Metastatic","date":"2026-06-03","time_local":"14:15","room":"E450"},"title":"Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-945","authors":[{"name":"M. Reck","affiliation":"Peter MacCallum Cancer Centre","is_presenter":true},{"name":"J. Brahmer","affiliation":"Stanford Cancer Institute","is_presenter":false},{"name":"S. Modi","affiliation":"Karolinska Institute","is_presenter":false},{"name":"L. Paz-Ares","affiliation":"Johns Hopkins Kimmel Cancer Center","is_presenter":false},{"name":"H. Rugo","affiliation":"Chinese University of Hong Kong","is_presenter":false}],"sponsor":"AstraZeneca","trial":{"name":"OlympiA-945","nct_id":"NCT19121013","phase":"III"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"olaparib","brand":"Lynparza","moa":"PARP inhibitor"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":37.4,"unit":"months","hr":0.78,"hr_ci95":[0.66,0.9],"p":"0.002"},{"name":"PFS","value":21.5,"unit":"months","hr":0.74,"hr_ci95":[0.68,0.92],"p":"0.002"},{"name":"ORR","value":68.8,"unit":"percent"}],"summary":"Median OS 37.4 months. HR 0.78 (95% CI 0.66–0.9). No new safety signals identified.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-03T14:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1588","abstract_number":"1588","doi":"10.1200/JCO.2026.44.17_suppl.1588","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"21:15","room":"E450"},"title":"Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-335 study)","authors":[{"name":"G. Curigliano","affiliation":"Dana-Farber Cancer Institute","is_presenter":true},{"name":"S. Tolaney","affiliation":"Massachusetts General Hospital","is_presenter":false},{"name":"J. Cortes","affiliation":"Karolinska Institute","is_presenter":false}],"sponsor":"Novartis","trial":{"name":"MONALEESA-335","nct_id":"NCT28129246","phase":"II"},"indication":"HR+ breast cancer","intervention":{"drug_inn":"ribociclib","brand":"Kisqali","moa":"CDK4/6 inhibitor"},"comparator":"standard of care","endpoints":[{"name":"OS","value":32.7,"unit":"months","hr":0.66,"hr_ci95":[0.55,0.77],"p":"<0.001"},{"name":"PFS","value":21,"unit":"months","hr":0.7,"hr_ci95":[0.56,0.78],"p":"<0.001"},{"name":"ORR","value":65.5,"unit":"percent"}],"summary":"Median OS 32.7 months. HR 0.66 (95% CI 0.55–0.77). Grade ≥3 AEs consistent with prior reports.","competitive_relevance":"high","embargo":{"lifted_at":"2026-06-05T21:15:00-05:00","status":"embargoed"}},{"abstract_id":"2026-1048","abstract_number":"1048","doi":"10.1200/JCO.2026.44.17_suppl.1048","meeting":"ASCO Annual Meeting","meeting_city":"Chicago, IL","meeting_year":2026,"track":"Breast Cancer—Metastatic","session":{"type":"Poster Session","title":"Poster Session: Breast Cancer—Metastatic","date":"2026-06-05","time_local":"15:45","room":"Hall B1"},"title":"Real-world effectiveness of Trodelvy vs standard of care in TNBC","authors":[{"name":"H. Rugo","affiliation":"Royal Marsden Hospital","is_presenter":true},{"name":"C. Robert","affiliation":"Peter MacCallum Cancer Centre","is_presenter":false},{"name":"R. Herbst","affiliation":"UCSF Helen Diller Family Comprehensive Cancer Center","is_presenter":false},{"name":"S. Tolaney","affiliation":"Vall d'Hebron Institute of Oncology","is_presenter":false}],"sponsor":"Gilead","trial":{"name":"ASCENT-358","nct_id":"NCT73831897","phase":"III"},"indication":"TNBC","intervention":{"drug_inn":"sacituzumab govitecan","brand":"Trodelvy","moa":"anti-Trop-2 ADC"},"comparator":"docetaxel","endpoints":[{"name":"OS","value":23.2,"unit":"months","hr":0.72,"hr_ci95":[0.6,0.84],"p":"0.002"},{"name":"PFS","value":9.4,"unit":"months","hr":0.77,"hr_ci95":[0.59,0.83],"p":"0.002"},{"name":"ORR","value":50.9,"unit":"percent"}],"summary":"Median OS 23.2 months. HR 0.72 (95% CI 0.6–0.84). No new safety signals identified.","competitive_relevance":"low","embargo":{"lifted_at":"2026-06-05T15:45:00-05:00","status":"embargoed"}}]}